Basic Stats
| LEI | 549300O5S543GE2D9G67 |
| CIK | 1061027 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Viracta Therapeutics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| February 5, 2025 |
Viracta Therapeutics Announces Wind Down of Operations Exhibit 99.1 Viracta Therapeutics Announces Wind Down of Operations SAN DIEGO, February 5, 2025 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also ex |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2025 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 31, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 24, 2025 |
FORBEARANCE AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.1 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. FORBEARANCE AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FORBEARANCE AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 17, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 26, 2024 |
Exhibit 99.1 Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives SAN DIEGO, December 26, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a pr |
|
| November 29, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 10)1 Viracta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92765F108 (CUSIP Num |
|
| November 13, 2024 |
Exhibit 99.1 Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from expansion phase of the Phase 2 NAVAL-1 clinical trial of Nana-val in the first half of 2025 |
|
| November 13, 2024 |
First Amendment to Lease by and between the Company and Plastino II, LP, dated August 21, 2024. Exhibit 10.1 FIRST AMENDMENT TO LEASE between PLASTINO II, LP and VIRACTA THERAPEUTICS, INC. Effective August 21, 2024, Plastino II, LP, a California limited partnership, herein called "Landlord", and Viracta Theapeutics, Inc., herein called "Tenant", hereby consent to and make amendment to the Lease between Landlord and Tenant dated June 11, 2020, for that certain building space, known as Suite 2 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 6, 2024 |
Exhibit 99.1 Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten SAN DIEGO, November 6, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage preci |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 14, 2024 |
Exhibit 99.2 Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val’s substantial antitumor activity and generally well-tol |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 14, 2024 |
Exhibit 99.1 Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val’s substantial antitumor activity and generally well-tolerated safety profile - - New positive data and pr |
|
| August 14, 2024 |
Amended and Restated Outside Director Compensation Policy. Exhibit 10.2 VIRACTA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective April 1, 2024) Viracta Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors wh |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commissio |
|
| May 31, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2024 |
Employment Agreement by and between the Company and Michael Faerm, dated as of May 11, 2024 Exhibit 10.1 VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) by and between Viracta Therapeutics, Inc. (the “Company”) and Michael E. Faerm (“Executive”) is effective as of May 13, 2024 (the “Effective Date”). 1. Duties and Scope of Employment. (a) Positions and Duties. Executive will serve as Chief Financial Officer of the Company. Executive |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2024 |
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer Exhibit 99.1 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer San Diego, May 14, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. |
|
| May 9, 2024 |
Consulting Agreement by and between the Company and Daniel Chevallard, dated March 20, 2024. Exhibit 10.5 CONSULTING AGREEMENT This consulting agreement ("Agreement") is made by and between Viracta Therapeutics, Inc., having a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007 USA, together with its affiliates ("Company") and Daniel Chevallard, an individual with a place of business at [***] ("Consultant"), effective as of March 20, 2024 (one minute before the eff |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
Exhibit 99.1 Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate Nana-val’s ‘Kick an |
|
| April 26, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 09, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 20, 2024 |
Exhibit 10.1 VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) by and between Viracta Therapeutics, Inc. (the “Company”) and Melody Burcar (“Executive”) is effective as of September 30, 2022 (the “Effective Date”). 1. Duties and Scope of Employment. (a) Positions and Duties. Executive will serve as Vice President, Finance of the Company. Executi |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 7, 2024 |
Exhibit 10.31 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. AMENDMENT NO. 1 TO LICENSE AGREEMENT FOR RAF This Amendment No. 1 to License Agreement for RAF (this “Amendment”), effective as of March 4, 2024 (the “Amendment Effective |
|
| March 7, 2024 |
Exhibit 10.32 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. AMENDMENT NO. 1 TO ROYALTY PURCHASE AGREEMENT This Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is entered into as of March 4, 2024 (the “Amendment Ef |
|
| March 7, 2024 |
Exhibit 10.30 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIV |
|
| March 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viracta Therapeutics, Inc. |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-51531 VIRACTA THERAPE |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2024 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 7, 2024 |
Exhibit 10.33 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of March 1, 2024, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), |
|
| March 7, 2024 |
Exhibit 99.1 Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study expected in the second quarter of 2024 Completed enrollment |
|
| March 7, 2024 |
Exhibit 97.1 VIRACTA THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY As adopted on November 15, 2023 Viracta Therapeutics, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Compensation Committee (the “Committee”) of the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). |
|
| February 13, 2024 |
VIRX / Viracta Therapeutics, Inc. / FORWARD VENTURES V LP - SC 13G Passive Investment SC 13G 1 d744273dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viracta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92765F108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2023 |
First Amendment to Lease by and between the Company and Plastino II, LP, dated August 22, 2023 Exhibit 10.1 FIRST AMENDMENT TO LEASE between PLASTINO II, LP and VIRACTA THERAPEUTICS, INC. Effective August 21, 2023, Plastino II, LP, a California limited partnership, herein called "Landlord", and Viracta Theapeutics, Inc., herein called "Tenant'', hereby consent to and make amendment to the Lease between Landlord and Tenant dated August 1, 2020, for that certain building space, known as Suite |
|
| November 9, 2023 |
Exhibit 99.1 Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma showing an overall response rate and complete response rate of 40% Reported interim data from the Phase 1b/2 trial of Nana-val in adv |
|
| November 9, 2023 |
Executive Engagement Agreement by and between the Company and Darrel P. Cohen, dated August 7, 2023 Exhibit 10.2 VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) by and between Viracta Therapeutics, Inc. (the “Company”) and Darrel P. Cohen, M.D., Ph.D. (“Executive”) is effective as of August 7, 2023 (the “Effective Date”). 1. Duties and Scope of Employment. (a) Positions and Duties. Executive will serve as Chief Medical Officer of the Company |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 4, 2023 |
EX-99.1 Exhibit 99.1 Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers Preliminary clinical data from patients with relapsed/refractory EBV+ peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study demonstrated median duration of response extended to 1 |
|
| October 4, 2023 |
Exhibit 99.2 Viracta Therapeutics, Inc. October 2023 Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management of Viracta Therapeutics, Inc. (“Viracta” or the “Company”), includi |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 14, 2023 |
Exhibit 10.2 VIRACTA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective August 12, 2023) Viracta Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors |
|
| August 14, 2023 |
Exhibit 99.1 Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in pivotal NAVAL-1 study of Nana-val Prioritized EBV+ diffuse large B-cell lymphoma and EBV+ post-transplant lymphoproliferative disease as key f |
|
| August 7, 2023 |
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer Exhibit 99.1 Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer SAN DIEGO, Calif., August 7, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 8, 2023 |
Exhibit 99.1 Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023 Enrollment into fifth dose level in the dose escalation portion of the Phase 1b/2 |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Inco |
|
| May 5, 2023 |
Consulting Agreement between the Company and Lisa Rojkjaer, M.D., dated May 5, 2023 EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. CONSULTING AGREEMENT This consulting agreement (“Agreement”) is made by and between VI |
|
| May 2, 2023 |
Viracta Therapeutics Announces Departure of Chief Medical Officer EX-99.1 Exhibit 99.1 Viracta Therapeutics Announces Departure of Chief Medical Officer San Diego, May 2, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another oppor |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 27, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viracta Therapeutics, Inc. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 1 d482739ds8.htm S-8 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 94-3295878 (State or other jurisdiction of incorporati |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-51531 VIRACTA THERAPE |
|
| March 13, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 13, 2023 |
Exhibit 99.1 Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023 Completed initial enrollment into the fourth dose level i |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 9)1 Viracta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92765F108 (CUSIP Numb |
|
| January 10, 2023 |
VIRX / Viracta Therapeutics Inc / Schindel Yair Chaim - SC 13D/A Activist Investment SC 13D/A 1 zk2328999.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Viracta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92765F108 (CUSIP Number) aMoon Growth Fund Limited Partnership aMoon-VRCT SPV Limited Partnership aMoon |
|
| November 10, 2022 |
Exhibit 99.1 Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to Stage 2 now anticipated in the first half of 2023 Completed initial enrollment of |
|
| November 10, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of August 26, 2022, by and among SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054, as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on Schedule 1.1 thereof |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction (Commission (IRS Employ |
|
| September 19, 2022 |
Exhibit 10.1 VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this ?Agreement?) by and between Viracta Therapeutics, Inc. (the ?Company?) and Mark Rothera (?Executive?) is effective as of September 19, 2022 (the ?Effective Date?). 1. Duties and Scope of Employment. (a) Positions, Authority and Duties. Executive will serve as Chief Executive Officer and |
|
| September 19, 2022 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Ivor Royston (?Executive?) and Viracta Therapeutics, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS WHEREAS, Executive was employed by the Company as its Chief Executive Officer; WHEREAS, Executive signed an Ex |
|
| September 19, 2022 |
Exhibit 99.1 Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company?s Strategic Development and Growth Viracta Therapeutics? Board of Directors appoints Mark Rothera as President and Chief Executive Officer Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of Viracta?s Board of Directors PR Newswire, San D |
|
| August 26, 2022 |
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 99.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of August 26, 2022, by and among SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054, as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on Schedule 1.1 thereof |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2022 |
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors Exhibit 99.1 Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors PR Newswire, San Diego, August 11, 2022 ? Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors. ?Ms. Chung?s unique combination of commercial and e |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2022 |
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates Exhibit 99.1 Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) expanding into Stage 2 is anticipated in the fourth quarter of 2022 Advanced the Phase 1b/2 trial of Nana-val in EBV+ solid tumors into the se |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| June 27, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viracta Therapeutics, Inc. |
|
| June 27, 2022 |
As filed with the Securities and Exchange Commission on June 27, 2022 As filed with the Securities and Exchange Commission on June 27, 2022 Registration No. |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commission |
|
| June 8, 2022 |
2022 Employee Stock Purchase Plan. Exhibit 10.1 VIRACTA THERAPEUTICS, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a Code Section 423 Component (?423 Component?) and a non-Code Section 423 Component ( |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2022 |
Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates Exhibit 99.1 Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) that have advanced into Stage 2 anticipated in the second half of 2022 Preliminary safety and efficacy data for the Phase 1b/2 trial of |
|
| April 27, 2022 |
DEFA14A 1 d340600ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 18, 2022 |
As filed with the Securities and Exchange Commission on March 18, 2022 As filed with the Securities and Exchange Commission on March 18, 2022 Registration No. |
|
| March 18, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viracta Therapeutics, Inc. |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-51531 VIRACTA THERAPE |
|
| March 17, 2022 |
Exhibit 21.1 Subsidiaries of Viracta Therapeutics, Inc.* Name of Subsidiary Jurisdiction of Incorporation or Organization Viracta Subsidiary, Inc. Delaware Viracta Royalty Fund, LLC Delaware * Inclusion on the list above is not an admission that any of the above entities, individually or in the aggregate, constitutes a significant subsidiary within the meaning of Rule 1-02(w) of Regulation S-X and |
|
| March 17, 2022 |
Exhibit 10.28 VIRACTA THERAPEUTICS, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company?s objectives. 2. Definitions. 2.1 ?Actual Award? means as to any Performance Period, the actual award (if any) payab |
|
| March 16, 2022 |
Viracta Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Final Phase 1b/2 data showing promising and durable signal of efficacy for Nana-val in patients with relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma featured in an oral presentation at ASH 2021 Pivotal NAVAL-1 trial of Nana-val for the treatment of EBV+ lymphoma is enrolling patients and an update on the initial cohort(s) expanding into Stage 2 is anticipated in the second half of 2022 Preliminary safety and efficacy data from the Phase 1b/2 trial of Nana-val for the treatment of advanced EBV+ solid tumors is expected in the second half of 2022 Cash balance of $103. |
|
| March 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 15, 2022 |
VIRX / Viracta Therapeutics Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.) (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92765F108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2022 |
EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| February 14, 2022 |
VIRX / Viracta Therapeutics Inc / Aisling Capital IV, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Viracta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92765F108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the Rule Pursuant to Which th |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 8)1 Viracta Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92765F108 (CUSIP Numb |
|
| February 9, 2022 |
VIRX / Viracta Therapeutics Inc / FORWARD VENTURES V LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viracta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92765F108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| December 1, 2021 |
144 1 d246357d144.htm 144 OMB APPROVAL OMB Number: 3235-0101 Expires: June 30, 2020 Estimated average burden hours per response 1.00 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 SEC USE ONLY DOCUMENT SEQUENCE NO. CUSIP NUMBER WORK LOCATION ATTENTION: Transmit for filing 3 |
|
| December 1, 2021 |
OMB APPROVAL OMB Number: 3235-0101 Expires: June 30, 2020 Estimated average burden hours per response 1. |
|
| December 1, 2021 |
144 1 d214434d144.htm 144 OMB APPROVAL OMB Number: 3235-0101 Expires: June 30, 2020 Estimated average burden hours per response 1.00 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 SEC USE ONLY DOCUMENT SEQUENCE NO. CUSIP NUMBER WORK LOCATION ATTENTION: Transmit for filing 3 |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2021 |
Exhibit 99.1 Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced that final results of Phase 1b/2 trial of nanatinostat and valganciclovir (Nana-val) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma were selected for an oral presentation at the 2021 American Society of Hematology (ASH) Annual Meeting Continued the global |
|
| November 10, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[***]?. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to tim |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 5, 2021 |
Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance Exhibit 99.1 Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance PR Newswire, San Diego, November 5, 2021 ? Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, today announced that the Company has entered into a loan and security agreement with Silicon Valley Bank (SVB |
|
| October 6, 2021 |
Exhibit 99.1 Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors Multinational trial expands Viracta?s clinical-stage pipeline beyond EBV+ lymphoproliferative disorders PR Newswire, San Diego, October 6, 2021 ? Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiatio |
|
| October 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 06, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 23, 2021 |
Exhibit 10.1 MUTUAL TERMINATION AGREEMENT THIS MUTUAL TERMINATION AGREEMENT (?Agreement?) is made and entered into this 20th day of August, 2021 (?Effective Date?), by and between Viracta Subsidiary, Inc. (formerly Viracta Therapeutics, Inc.), a Delaware corporation (?Viracta?), and Salubris Pharmaceutical Co. Ltd., a company organized under the laws of the People?s Republic of China (?Salubris?). |
|
| August 23, 2021 |
Exhibit 99.1 Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China Viracta now controls global rights to its all-oral combination regimen of nanatinostat and valganciclovir PR Newswire, San Diego, August 23, 2021 ? Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancie |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 16, 2021 |
Exhibit 99.1 Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors PR Newswire, San Diego, August 16, 2021 ? Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointments of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51531 94-3295878 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 12, 2021 |
Exhibit 10.4 VIRACTA THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this ?Amendment?) by and between Viracta Therapeutics, Inc. (the ?Company?) and Ivor Royston, M.D. (?Executive?) is effective as of August 12, 2021. WHEREAS, the Company and Executive are parties to that certain Employment Agreement, effective as of April 3, 2017 (the ?Original Agreeme |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commiss |
|
| August 12, 2021 |
Exhibit 10.3 VIRACTA THERAPEUTICS, INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonsta |
|
| August 12, 2021 |
Viracta Therapeutics, Inc. August 2021 Exhibit 99.2 Forward Looking Statements This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management of Viracta Therapeutics, Inc. (?Viracta? or the ?Company?), includ |
|
| August 12, 2021 |
Exhibit 99.1 Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates Initiated NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma Received FDA clearance of IND application for a Phase 1b/2 trial in EBV-positive solid tumors Strengthened management team with the appointment of Ayman Elguindy, Ph.D., a |
|
| August 12, 2021 |
Exhibit 10.6 VIRACTA THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this ?Amendment?) by and between Viracta Therapeutics, Inc. (the ?Company?) and Dr. Lisa Rojkjaer (?Executive?) is effective as of August 12, 2021. WHEREAS, the Company and Executive are parties to that certain Employment Agreement, effective as of May 1, 2020 (the ?Original Agreement? |
|
| August 12, 2021 |
Exhibit 10.5 VIRACTA THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this ?Amendment?) by and between Viracta Therapeutics, Inc. (the ?Company?) and Daniel R. Chevallard, CPA (?Executive?) is effective as of August 12, 2021. WHEREAS, the Company and Executive are parties to that certain Employment Agreement, effective as of July 29, 2019 (the ?Original |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| July 21, 2021 |
Exhibit 99.1 Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors Third combination trial with nanatinostat and valganciclovir broadens scope beyond EBV+ lymphoproliferative disorders Trial initiation expected in H2 2021 PR Newswire, San Diego, July 21, 2021 ? Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision o |
|
| July 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction (Commission (IRS Employer of |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commissio |
|
| June 2, 2021 |
CORRESP 1 filename1.htm June 2, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz Re: Viracta Therapeutics, Inc. Registration Statement on Form S-3 Filed May 28, 2021 File No. 333-256647 Acceleration Request Requested Date: June 4, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlem |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commission |
|
| May 28, 2021 |
Exhibit 10.2 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of May 27, 2021, by and between Silicon Valley Bank (?Bank?) and Viracta Subsidiary, Inc. (f/k/a Viracta Therapeutics, Inc.), a Delaware corporation (?Borrower?), whose address is 2533 South Coast Highway 101, Suite 201, Cardiff by the Sea, CA 92007. |
|
| May 28, 2021 |
Exhibit 10.1 OPEN MARKET SALE AGREEMENTSM May 28, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Viracta Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common |
|
| May 28, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on May 28, 2021 Registration No. |
|
| May 13, 2021 |
EX-10.13 3 d51517dex1013.htm EX-10.13 Exhibit 10.13 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. ROYALTY PURCHASE AGREEMENT dated as of March 22, 2021 between VIRACTA THERAPEUTICS, INC., as Seller, and XOMA (US) LLC, as Purchaser |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 Commission File Number 000-51531 VIRACTA THERAPEUTICS, INC. (Exact nam |
|
| May 13, 2021 |
Exhibit 10.12 VIRACTA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective March 31, 2021) Viracta Therapeutics, Inc. (the ?Company?) believes that the granting of equity and cash compensation to members of the Company?s Board of Directors (the ?Board,? and members of the Board, ?Directors?) represents an effective tool to attract, retain and reward Directors |
|
| May 12, 2021 |
DESCRIPTION OF VIRACTA’S BUSINESS Exhibit 99.2 DESCRIPTION OF VIRACTA?S BUSINESS Overview Viracta Therapeutics, Inc. (?Viracta?) is a clinical-stage, precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. The association of viruses and cancer has been well characterized, and Viracta?s lead program is focused on cancers associated with the Epstein-Barr virus (?EBV?). EBV ha |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction (Commission (IRS Employer of |
|
| May 12, 2021 |
Exhibit 99.1 Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma is on track to be initiated in Q2 2021 NAVAL-1 trial design to be featured in a Key Opinion Leader webinar taking place on May 20, 2021 Closed merger with Sunesis Pharmaceuticals and |
|
| April 14, 2021 |
EX-99.1 Exhibit 99.1 VIRACTA CORPORATE OVERVIEW NASDAQ: VIRX I WWW.VIRACTA.COM Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management, including, without limitation, statement |
|
| April 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commissi |
|
| April 2, 2021 |
S-8 1 d269015ds8.htm S-8 As filed with the Securities and Exchange Commission on April 2, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3295878 (State or other jurisdiction of incorporatio |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commissi |
|
| March 23, 2021 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION EX-99.2 4 d67342dex992.htm EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Merger On February 24, 2021, Sunesis Pharmaceuticals, Inc. (the “Company” or “Sunesis”) completed its business combination with Viracta Therapeutics, Inc. (“Viracta”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated November 29, 2020, by and among the Compan |
|
| March 23, 2021 |
Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commissi |
|
| March 23, 2021 |
Report of Independent Registered Public Accounting Firm EX-99.1 Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors of Viracta Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of Viracta Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related statements of operations and comprehensive loss, convertible preferred stock |
|
| March 23, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction (Commission (IRS Emplo |
|
| March 11, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.) (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92765F108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, |
|
| March 8, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viracta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92765F108 (CUSIP Number) February 25, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| March 5, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Viracta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92765F108 (CUSIP Number) February 25, 2021 (Date of Event Which Re |
|
| March 4, 2021 |
EX-99.1 Exhibit 99.1 Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors Cheryl A. Madsen, RAC appointed as Senior Vice President, Regulatory Affairs PR Newswire, San Diego, March 4, 2021 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commissio |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Viracta Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92765F108 (CUSIP Number) aMoon Growth Fund Limited Partnership aMoon-VRCT SPV Limited Partnership aMoon Growth Fund G.P. Limited Partnership aMoon General P |
|
| March 2, 2021 |
EX-99 2 exhibit4.htm EXHIBIT 4 EXHIBIT 4 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13D (the “Schedule 13D”), filed by the undersigned with respect to shares of common stock, par value $0.0001 per share, of Viracta Therapeutics, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1 |
|
| February 24, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SUNESIS PHARMACEUTICALS, INC. SUNESIS PHARMACEUTICALS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the Corporation is Sunesis Pharmaceuticals, Inc. SECOND: The origina |
|
| February 24, 2021 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SUNESIS PHARMACEUTICALS, INC. SUNESIS PHARMACEUTICALS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the Corporation is Sunesis Pharmaceuticals, Inc. SECOND: The origina |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51531 SUNESIS PHARMACEUTICALS INC. (Exact name of registrant as specified |
|
| February 24, 2021 |
EX-99.1 Exhibit 99.1 Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol “VIRX” Cash and cash equivalents of over $120 million as of merger close Registration trial for the treatment of relapsed/refractory EBV-positive lymphoma expec |
|
| February 24, 2021 |
Exhibit 4.1 Description of the Capital Stock The following is a description of the common stock, $0.0001 par value per share (?Common Stock?) of Sunesis Pharmaceuticals, Inc. (the ?Company?), which is the only security of the Company registered pursuant to Section 12 of the Securities and Exchange Act of 1934, as amended. The following summary describes the material terms of our Common Stock. The |
|
| February 24, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Legal Name State or other Jurisdiction of Incorporation Sunesis Europe Limited United Kingdom |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Commi |
|
| February 23, 2021 |
8-K 1 snss-8k20210222.htm 8-K 2021 STOCKHOLDERS MEETING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2021 Date of Report (Date of earliest event reported) SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-329 |
|
| February 16, 2021 |
CUSIP No: 867328874 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Sunesis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 867328874 (CUS |
|
| February 16, 2021 |
Filed by Sunesis Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Viracta Therapeutics, Inc. (Commission File No. 000-51531) Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product C |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Class A Common Stock, Par Value $0.001, of Sunesis Pharmaceuticals INC beneficially owned by them, together with any or all amendments thereto, when and if |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SUNESIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 867328874 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 7)1 Sunesis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 867328874 (CUSIP N |
|
| February 12, 2021 |
Merger Prospectus - 8-K SHAREHOLDER LITIGATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Co |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Co |
|
| February 11, 2021 |
425 Filed by Sunesis Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Viracta Therapeutics, Inc. (Commission File No. 000-51531) Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences PR Newswire, San Diego, February 11, 2021 – |
|
| January 14, 2021 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-251567 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Sunesis Pharmaceuticals, Inc. and Viracta Therapeutics, Inc.: Sunesis Pharmaceuticals, Inc. (“Sunesis”) and Viracta Therapeutics, Inc. (“Viracta”) have entered into an Agreement and Plan of Merger and Reorganization, dated November 29, 2020, as may |
|
| January 13, 2021 |
Consent of Thomas Darcy, as designee to the board of directors EX-99.9 Exhibit 99.9 January 12, 2021 Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Consent to Reference in Registration Statement Sunesis Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| January 13, 2021 |
Consent of Michael Huang, M.S., M.B.A., as designee to the board of directors EX-99.5 Exhibit 99.5 January 12, 2021 Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Consent to Reference in Registration Statement Sunesis Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| January 13, 2021 |
EX-10.26 Exhibit 10.26 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT This EXCLUSIVE COLLABORATION AND LICEN |
|
| January 13, 2021 |
Consent of Roger J. Pomerantz, M.D., as designee to the board of directors EX-99.7 Exhibit 99.7 January 12, 2021 Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Consent to Reference in Registration Statement Sunesis Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| January 13, 2021 |
2021 Equity Incentive Plan, and form agreements thereunder S-4/A 1 d82534ds4a.htm S-4/A Table of Contents As filed with the Securities and Exchange Commission on January 13, 2021 Registration No. 333-251567 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT Under The Securities Act of 1933 Sunesis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 28 |
|
| January 13, 2021 |
EX-10.24 Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. AMENDED AND RESTATED LICENSE AGREEMENT This AMENDED AND RESTATED LICENSE AGREEMENT ( |
|
| January 13, 2021 |
Consent of MTS Securities, LLC EX-99.1 Exhibit 99.1 January 12, 2021 Board of Directors Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letter, dated November 29, 2020, to the Board of Directors of Sunesis Pharmaceuticals, Inc. (“Sunesis”) as Annex B to, and reference to such opinion let |
|
| January 13, 2021 |
Consent of Ivor Royston, M.D., as designee to the board of directors EX-99.4 Exhibit 99.4 January 12, 2021 Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Consent to Reference in Registration Statement Sunesis Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| January 13, 2021 |
EX-10.28 Exhibit 10.28 LEASE 1. PARTIES. This Lease, dated, for reference purposes only, August 1 , 2020, is made by and between PLASTINO II, a limited partnership, (herein called “Landlord”) and Viracta Therapeutics, Inc. (herein called “Tenant”). Landlord and Tenant may each be referred to herein as a “Party” and collectively as the “Parties.” 2. PREMISES. Landlord does hereby lease to Tenant an |
|
| January 13, 2021 |
EX-10.27 Exhibit 10.27 LEASE 1. PARTIES. This Lease, dated, for reference purposes only, June 11, 2020, is made by and between PLASTINO II, a limited partnership, (herein called “Landlord”) and Viracta Therapeutics, Inc. (herein called “Tenant”). Landlord and Tenant may each be referred to herein as a “Party” and collectively as the “Parties.” 2. PREMISES. Landlord does hereby lease to Tenant and |
|
| January 13, 2021 |
EX-10.23 Exhibit 10.23 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE |
|
| January 13, 2021 |
EX-10.22 Exhibit 10.22 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of July 30, 2020 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and VIRACTA THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows |
|
| January 13, 2021 |
EX-10.18 Exhibit 10.18 VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is entered into as of May 31, 2017 (the “Agreement Date”) by and between Viracta Therapeutics, Inc. (the “Company”), and Ivor Royston (“Executive”), and effective as of April 3, 2017 (the “Effective Date”). 1. Duties and Scope of Employment. (a) Positions and Duti |
|
| January 13, 2021 |
EX-10.19 Exhibit 10.19 VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is entered into as of July 29, 2019, (the “Effective Date”) by and between Viracta Therapeutics, Inc. (the “Company”), and Daniel R. Chevallard, CPA (“Executive”). 1. Duties and Scope of Employment. (a) Positions and Duties. As of the Effective Date, Executive wil |
|
| January 13, 2021 |
EX-10.21 Exhibit 10.21 VIRACTA THERAPEUTICS, INC. AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits |
|
| January 13, 2021 |
EX-10.25 Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”) dated as of May 1, 2017 |
|
| January 13, 2021 |
Consent of Gur Roshwalb, M.D., as designee to the board of directors EX-99.8 Exhibit 99.8 January 12, 2021 Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Consent to Reference in Registration Statement Sunesis Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| January 13, 2021 |
EX-10.20 Exhibit 10.20 VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is entered into as of February 26, 2020, and becomes effective upon Dr. Lisa Rojkjaer’s first date of employment, provided such date occurs on or before May 1, 2020, (the “Effective Date”) by and between Viracta Therapeutics, Inc. (the “Company”), and Dr. Lisa Roj |
|
| January 13, 2021 |
EX-10.31 Exhibit 10.31 CONSULTING AGREEMENT Effective Date: January 1, 2021 Expiration Date: Earlier of [May 29], 2021 and the Closing of the Merger between Sunesis Pharmaceuticals, Inc. and Viracta Therapeutics, Inc. This Consulting Agreement (the “Consulting Agreement”) is entered into by and between Sunesis Pharmaceuticals, Inc. (“SUNESIS”) and Dayton Misfeldt (“CONSULTANT”) in connection with |
|
| January 13, 2021 |
Form of Proxy Card for the Sunesis’s Special Meeting of Stockholders EX-99.3 Exhibit 99.3 PRELIMINARY - SUBJECT TO COMPLETION VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com SUNESIS PHARMACEUTICALS, INC. 395 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO, CA 94080 Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in h |
|
| January 13, 2021 |
Consent of Sam Murphy, Ph.D., as designee to the board of directors EX-99.6 23 d82534dex996.htm EX-99.6 Exhibit 99.6 January 12, 2021 Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Consent to Reference in Registration Statement Sunesis Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as am |
|
| January 12, 2021 |
CORRESP 1 filename1.htm SUNESIS PHARMACEUTICALS, INC. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 January 12, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Sunesis Pharmaceuticals, Inc. Form S-4 Registration Statement (File No. 333-251567) Ladies and Gentlemen: Pursuant to Rule 461 promulgated u |
|
| January 7, 2021 |
425 1 d107568d425.htm 425 Filed by Sunesis Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Viracta Therapeutics, Inc. (Commission File No. 000-51531) Precision Oncology Company Targeting Virus-Associated Cancers January 2021 Corporate PresentationP |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sunesis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 867328874 (CUSIP Number) December 22, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| December 22, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) |
|
| December 22, 2020 |
S-4 Table of Contents As filed with the Securities and Exchange Commission on December 22, 2020 Registration No. |
|
| December 22, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) |
|
| December 22, 2020 |
Consent of MTS Securities, LLC. EX-99.1 Exhibit 99.1 December 22, 2020 Board of Directors Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letter, dated November 29, 2020, to the Board of Directors of Sunesis Pharmaceuticals, Inc. (“Sunesis”) as Annex B to, and reference to such opinion le |
|
| December 22, 2020 |
EX-10.29 Exhibit 10.29 EXECUTIVE SEVERANCE BENEFITS AGREEMENT This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into this day of , (the “Effective Date”) between (“Executive”) and SUNESIS PHARMACEUTICALS, INC. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain ca |
|
| December 7, 2020 |
425 Filed by Sunesis Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Viracta Therapeutics, Inc. (Commission File No. 000-51531) Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End |
|
| November 30, 2020 |
Form of Retention Benefits Letter between Sunesis Pharmaceuticals, Inc. and certain officers. EX-10.4 Exhibit 10.4 SUNESIS PHARMACEUTICALS, INC. November [ ], 2020 [EMPLOYEE NAME] RE: Exercise Period Extension and Retention Bonus Agreement Dear [EMPLOYEE NAME]: As you know, Sunesis Pharmaceuticals, Inc. (the “Company”) has executed an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), which, if the transactions contemplated thereby are consummated (the “Acquisition”) |
|
| November 30, 2020 |
EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), is made as of November 29, 2020, by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation (the “Parent”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares, par value $ per share (“Company Shares”), of Vi |
|
| November 30, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction (Commission (IRS |
|
| November 30, 2020 |
Form of Sunesis Pharmaceuticals, Inc. Support Agreement, dated November 29, 2020. EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), is made as of November 29, 2020, by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation (the “Parent”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares, par value $ per share (“Company Shares”), of Vi |
|
| November 30, 2020 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SUNESIS PHARMACEUTICALS, INC. a Delaware corporation; SOL MERGER SUB, INC., a Delaware corporation; and VIRACTA THERAPEUTICS, INC., a Delaware corporation Dated as of November 29, 2020 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 |
|
| November 30, 2020 |
EX-99.3 Exhibit 99.3 On November 30, 2020, Sunesis Pharmaceuticals, Inc. (“Sunesis”) and Viracta Therapeutics, Inc. (“Viracta”) hosted an investor conference call at 5:30 a.m. Eastern Time to discuss the entering into a definitive merger agreement under which Viracta will merge with a wholly-owned subsidiary of Sunesis in an all-stock transaction. The script of the conference call related to such |
|
| November 30, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction (Commission (IRS |
|
| November 30, 2020 |
EX-10.2 Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), is made as of November 29, 2020, by and between Viracta Therapeutics, Inc., a Delaware corporation (the “Company”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares, par value $0.0001 per share (“Parent Shares”), of |
|
| November 30, 2020 |
EX-99.1 Exhibit 99.1 Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading instituti |
|
| November 30, 2020 |
EX-99.2 Precision Oncology Company Targeting Virus-Associated Cancers November 30, 2020 Exhibit 99.2 This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: expected timing, completion and effects of the proposed merger of Sunesis Pharmaceutics, Inc, (“Sunesis”) and Vir |
|
| November 30, 2020 |
EX-99.2 Precision Oncology Company Targeting Virus-Associated Cancers November 30, 2020 Exhibit 99.2 This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: expected timing, completion and effects of the proposed merger of Sunesis Pharmaceutics, Inc, (“Sunesis”) and Vir |
|
| November 30, 2020 |
EX-10.3 Exhibit 10.3 Confidential Lock-Up Agreement November 29, 2020 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of November 29, 2020 (the “Merger Agreement”), with VIRACTA THERAPEUTICS, INC., a Delaware corporation (th |
|
| November 30, 2020 |
EX-3.1 Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF SUNESIS PHARMACEUTICALS, INC. The Amended and Restated Bylaws (the “Bylaws”) of Sunesis Pharmaceuticals, Inc., a Delaware corporation, are hereby amended as follows, effective immediately, by adding a new Article XI, which shall read in its entirety as follows: ARTICLE XI – EXCLUSIVE FORUM (i) Unless the corporation consents in wri |
|
| November 30, 2020 |
Amendment to Amended and Restated Bylaws of Sunesis Pharmaceuticals, Inc. EX-3.1 Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF SUNESIS PHARMACEUTICALS, INC. The Amended and Restated Bylaws (the “Bylaws”) of Sunesis Pharmaceuticals, Inc., a Delaware corporation, are hereby amended as follows, effective immediately, by adding a new Article XI, which shall read in its entirety as follows: ARTICLE XI – EXCLUSIVE FORUM (i) Unless the corporation consents in wri |
|
| November 30, 2020 |
EX-99.1 Exhibit 99.1 Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading instituti |
|
| November 30, 2020 |
Form of Retention Benefits Letter between Sunesis Pharmaceuticals, Inc. and certain officers EX-10.4 Exhibit 10.4 SUNESIS PHARMACEUTICALS, INC. November [ ], 2020 [EMPLOYEE NAME] RE: Exercise Period Extension and Retention Bonus Agreement Dear [EMPLOYEE NAME]: As you know, Sunesis Pharmaceuticals, Inc. (the “Company”) has executed an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), which, if the transactions contemplated thereby are consummated (the “Acquisition”) |
|
| November 30, 2020 |
Form of Viracta Therapeutics, Inc. Support Agreement, dated November 29, 2020. EX-10.2 Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), is made as of November 29, 2020, by and between Viracta Therapeutics, Inc., a Delaware corporation (the “Company”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares, par value $0.0001 per share (“Parent Shares”), of |
|
| November 30, 2020 |
Exhibit 99.3 On November 30, 2020, Sunesis Pharmaceuticals, Inc. (“Sunesis”) and Viracta Therapeutics, Inc. (“Viracta”) hosted an investor conference call at 5:30 a.m. Eastern Time to discuss the entering into a definitive merger agreement under which Viracta will merge with a wholly-owned subsidiary of Sunesis in an all-stock transaction. The script of the conference call related to such proposed |
|
| November 30, 2020 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SUNESIS PHARMACEUTICALS, INC. a Delaware corporation; SOL MERGER SUB, INC., a Delaware corporation; and VIRACTA THERAPEUTICS, INC., a Delaware corporation Dated as of November 29, 2020 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 |
|
| November 30, 2020 |
Form of Lock-Up Agreement, dated November 29, 2020. EX-10.3 Exhibit 10.3 Confidential Lock-Up Agreement November 29, 2020 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of November 29, 2020 (the “Merger Agreement”), with VIRACTA THERAPEUTICS, INC., a Delaware corporation (th |
|
| November 16, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Co |
|
| November 16, 2020 |
Exhibit 99.1 Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 Par Hyare Sunesis Pharmaceuticals, Inc. 650-266-3784 Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., November 16, 2020 (GLOBE NEWSWIRE) - Sunesis Pharmaceuticals, Inc. (Nasdaq: |
|
| November 16, 2020 |
Quarterly Report - 10-Q Q3 2020 10-Q 1 snss-10q20200930.htm 10-Q Q3 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t |
|
| September 18, 2020 |
Other Events - 8-K REGAINED NASDAQ COMPLIANCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (C |
|
| September 2, 2020 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SUNESIS PHARMACEUTICALS, INC. SUNESIS PHARMACEUTICALS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the Corporation is Sunesis Pharmaceuticals, Inc. SECOND: The origina |
|
| September 2, 2020 |
Financial Statements and Exhibits - 8-K REVERSE STOCK SPLIT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3295878 (State or other jurisdiction of incorporation) (Co |
|
| August 11, 2020 |
Financial Statements and Exhibits 8-K 1 snss-8k20200811.htm 8-K Q2'20 EARNINGS PRESS RELEASE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 SUNESIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51531 94-3 |
|
| August 11, 2020 |
Exhibit 10.2 EXECUTIVE SEVERANCE BENEFITS AGREEMENT This Executive Severance Benefits Agreement (the “Agreement”) is entered into this 4th day of May, 2020 (the “Effective Date”) between Constantina Gullotta (“Executive”) and Sunesis Pharmaceuticals, Inc. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of spec |
|
| August 11, 2020 |
Exhibit 99.1 Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 Par Hyare Sunesis Pharmaceuticals, Inc. 650-266-3784 Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., August 11, 2020 (GLOBE NEWSWIRE) - Sunesis Pharmaceuticals, Inc. (Nasdaq: S |
